MaxCyte Form 4: Cynthia Collins Adds 80,889 Total Shares via Equity Award

Rhea-AI Filing Summary

MaxCyte, Inc. (MXCT) – Form 4 insider filing dated 06/23/2025

Independent director Cynthia Collins reported an annual equity grant under the company’s non-employee director compensation program. The grant consists of:

• 29,210 restricted stock units (RSUs) awarded on 06/18/2025 at no cost; each RSU converts into one common share upon vesting on 06/18/2026, assuming continuous board service.
• 50,790 stock options with an exercise price of $2.11 per share, expiring 06/17/2035. Vesting details beyond the standard one-year cliff for RSUs were not disclosed in the filing.

Following the grant, Collins’ direct beneficial ownership increased to 80,889 common shares, strengthening alignment between the director and shareholders. Because the RSUs and options were granted by the company rather than purchased on the open market, the transaction incurs no immediate cash outlay by the insider and does not provide new pricing insight to investors.

No sales, dispositions, or other derivative transactions were reported, and the filing does not contain financial performance data or forward-looking statements. Overall, this is a routine governance disclosure reflecting the company’s ongoing equity-based compensation practice for directors.

Positive

• Director’s beneficial ownership rises to 80,889 shares, marginally increasing insider alignment with shareholders.
• No shares were sold, indicating continued confidence and commitment by the director.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director equity grant; improves alignment, minimal market impact.

The filing shows MaxCyte issued standard annual equity to director Cynthia Collins—29,210 RSUs and 50,790 options at $2.11. Such grants are customary for U.S. small-cap biotech boards and create modest additional dilution but enhance director–shareholder alignment. Because the RSUs vest in one year and the options are out-of-the-money unless MXCT trades above $2.11, immediate valuation impact is negligible. No open-market buying or selling occurred, so signal value is limited. Investors may view continued board retention positively, yet the transaction does not materially change ownership structure or capital allocation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Cynthia

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		29,210(1)(2)	A	$0	80,889	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.11	06/18/2025		A		50,790		(2)	06/17/2035	Common Stock	50,790	$0	50,790	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date.

	/s/ David Sandoval, Attorney-in-Fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MaxCyte (MXCT) disclose in the latest Form 4?

MXCT reported a routine annual grant of 29,210 RSUs and 50,790 stock options to director Cynthia Collins.

How many shares does Cynthia Collins now own in MXCT?

After the grant, Collins directly beneficially owns 80,889 common shares.

What is the exercise price and expiration of the new MXCT options?

The options have a $2.11 exercise price and expire on 06/17/2035.

When will the 29,210 RSUs granted to Cynthia Collins vest?

The RSUs vest on 06/18/2026, subject to continuous board service.

Did the director purchase any MXCT shares on the open market?

No. The filing only reflects company-granted RSUs and options; no open-market purchases were reported.